Eli Lilly (LLY) has raised the price of its weight loss drug Mounjaro in the U.K. by as much as 170%, The Financial Times’ Hannah Kuchler reports. The increase in the cost of the shot, which also used to treat diabetes, starting in September will “address pricing inconsistencies compared with other developed countries, including in Europe,” according to the report. Lilly is not raising the price paid by the NHS and is working with private healthcare providers to maintain access to the medication, Kuchler writes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly, Superluminal Medicines announce collaboration
- Eli Lilly (LLY) CEO Buys $1 Million of Company Stock After Recent Crash
- Pharma tariff announcement likely ‘weeks away,’ Reuters reports
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- CoreWeave reports Q2 beat, Gildan to acquire Hanesbrands: Morning Buzz